ADPT
Adaptive Biotechnologies Corp
$16.70
-1.18%
$2.8B
No data for this timeframe.
Vol
Market Cap$2.8B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders6 funds
Inst. Value$243.4M
Inst. Activity1 buys / 2 sells
Insider Activity0B / 19S
Insider Net $-$5.5M
SEC Reports10
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. WA·CIK 0001478320·Prev Close $16.90
Recent Activity
Jun 9, 2026
SEC
Two C-suite insiders at Adaptive Biotechnologies sold a combined $893K in open-market transactions within a 7-day window
CLUSTER — Impact 3/10
Jun 4, 2026
Insider
BOBULSKY SUSAN sold 11,000 shares
Chief Commercial Officer, MRD @ $18.00 ($198.0K)
Jun 4, 2026
Insider
LO FRANCIS sold 5,792 shares
Chief People Officer @ $12.14 ($70.3K)
Jun 4, 2026
Insider
LO FRANCIS sold 39,741 shares
Chief People Officer @ $17.49 ($695.1K)
Jun 2, 2026
short_volume
Short Volume: ADPT — 58.5% short (0.4M / 0.6M)
Short: 361,774 | Exempt: 1,669 | TRF Vol: 618,652 | Short Ratio: 58.5% | Off-exchange volume (dark p
May 5, 2026
SEC
Adaptive Biotechnologies reported Q1 2026 revenue of $70.9M (up 35% YoY), beating consensus estimates on EPS ($-0.13 vs
8-K — Impact 8/10
Apr 24, 2026
SEC
Adaptive Biotechnologies (ADPT) is holding its 2026 annual shareholder meeting to vote on three key proposals: electing
DEFA14A — Impact 3/10
Inst.
BANK OF AMERICA CORP — TRIM
806,272 shares ($13.1M)
Price Targets
$20.14
+16.0% upside
Buy
Current $17.36
Low $18.00
Median $20.00
High $22.00
7 analysts
$18.00
$22.00
Analyst Ratings
5Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 12, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
| May 6, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| May 6, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
| May 6, 2026 | Guggenheim | REITERATE | Buy → Buy |
| May 6, 2026 | BTIG | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.14 ▲ +1.0% | $-0.15 — $-0.11 | 20% YoY | 7 |
| Next Q | $-0.11 | $-0.12 — $-0.10 | -289% YoY | 7 |
| Current FY | $-0.46 ▲ +2.0% | $-0.48 — $-0.43 | -17% YoY | 7 |
| Next FY | $-0.25 ▲ +5.3% | $-0.33 — $-0.17 | 45% YoY | 7 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Two C-suite insiders at Adaptive Biotechnologies sold a combined $893K in open-market transactions within a 7-day window
Jun 9, 2026
BULLISH
8-K
8/10
Adaptive Biotechnologies reported Q1 2026 revenue of $70.9M (up 35% YoY), beating consensus estimates on EPS ($-0.13 vs
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $183.2M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $19.1M | NEW |
| MORGAN STANLEY | $18.7M | DOUBLED |
| BANK OF AMERICA CORP | $13.1M | TRIM |
| FMR LLC | $6.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | BOBULSKY SUSAN | SELL | $198.0K |
| Jun 4, 2026 | LO FRANCIS | M | $70.3K |
| Jun 4, 2026 | LO FRANCIS | SELL | $695.1K |
| Jun 4, 2026 | LO FRANCIS | M | $0.00 |
| May 18, 2026 | PISKEL KYLE | SELL | $40.6K |
6 institutional holders with $243.4M total value (14,987,509 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, MORGAN. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 11,282,152 | $183.2M | 75.3% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,173,535 | $19.1M | 7.8% | NEW |
| 3 | MORGAN STANLEY | 1,149,082 | $18.7M | 7.7% | DOUBLED +102.9% |
| 4 | BANK OF AMERICA CORP /DE/ | 806,272 | $13.1M | 5.4% | TRIM -49.5% |
| 5 | FMR LLC | 386,084 | $6.3M | 2.6% | — |
| 6 | WELLS FARGO & COMPANY/MN | 190,384 | $3.1M | 1.3% | ADD +65.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | TRIM | 1,597,999 | 806,272 | -49.5% | $13.1M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 114,785 | 190,384 | +65.9% | $3.1M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 279,700 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 49,900 | 279,700 | +460.5% | $4.2M | 2025-Q3 |
| UBS Group AG | TRIM | 455,406 | 253,980 | -44.2% | $3.8M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 78,772 | 114,785 | +45.7% | $1.7M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,471,553 | 1,857,168 | +26.2% | $21.6M | 2025-Q2 |
| UBS Group AG | ADD | 275,617 | 455,406 | +65.2% | $5.3M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 105,885 | 49,900 | -52.9% | $581.3K | 2025-Q2 |
| UBS Group AG | TRIM | 397,258 | 275,617 | -30.6% | $2.0M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 229,785 | 105,885 | -53.9% | $786.7K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 183,838 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 73,151 | 397,258 | +443.1% | $2.4M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 169,400 | 229,785 | +35.6% | $1.4M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 54,479 | 69,286 | +27.2% | $415.4K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 516,460 | 1,048,132 | +102.9% | $5.4M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 916,743 | — | $4.7M | 2024-Q3 |
5 unique insiders with 19 transactions. Net insider value: -$5.5M ($0.00 bought, $5.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | BOBULSKY SUSAN | Chief Commercial Officer, MRD | SELL | 11,000 | $18.00 | $198.0K |
| Jun 4, 2026 | LO FRANCIS | Chief People Officer | M | 5,792 | $12.14 | $70.3K |
| Jun 4, 2026 | LO FRANCIS | Chief People Officer | SELL | 39,741 | $17.49 | $695.1K |
| Jun 4, 2026 | LO FRANCIS | Chief People Officer | M | 5,792 | $0.00 | $0.00 |
| May 18, 2026 | PISKEL KYLE | Chief Financial Officer | SELL | 3,115 | $13.04 | $40.6K |
| Apr 27, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,707 | $8.46 | $124.4K |
| Apr 27, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 19,037 | $14.23 | $270.9K |
| Apr 27, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,707 | $0.00 | $0.00 |
| Apr 24, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $8.46 | $124.5K |
| Apr 24, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 19,060 | $14.02 | $267.2K |
| Apr 24, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 23, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $8.46 | $124.5K |
| Apr 23, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 19,060 | $13.74 | $261.9K |
| Apr 23, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 22, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $8.46 | $124.5K |
| Apr 22, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 19,060 | $14.13 | $269.3K |
| Apr 22, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 21, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $8.46 | $124.5K |
| Apr 21, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 30,941 | $14.66 | $453.6K |
| Apr 21, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 20, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $8.46 | $124.5K |
| Apr 20, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 19,060 | $14.55 | $277.3K |
| Apr 20, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 17, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $8.46 | $124.5K |
| Apr 17, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 19,060 | $14.57 | $277.7K |
| Apr 17, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 16, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $8.46 | $124.5K |
| Apr 16, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 19,060 | $14.18 | $270.3K |
| Apr 16, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 15, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $8.46 | $124.5K |
| Apr 15, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 19,060 | $14.61 | $278.5K |
| Apr 15, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 14, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $8.46 | $124.5K |
| Apr 14, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 19,060 | $14.56 | $277.5K |
| Apr 14, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 13, 2026 | RUBINSTEIN JULIE | President and COO | M | 8,109 | $7.27 | $59.0K |
| Apr 13, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 15,722 | $12.95 | $203.6K |
| Apr 13, 2026 | RUBINSTEIN JULIE | President and COO | M | 8,109 | $0.00 | $0.00 |
| Apr 10, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $7.27 | $107.0K |
| Apr 10, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 18,660 | $12.75 | $237.9K |
| Apr 10, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 9, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $7.27 | $107.0K |
| Apr 9, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 16,960 | $13.79 | $233.9K |
| Apr 9, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $0.00 | $0.00 |
| Apr 8, 2026 | ROBINS HARLAN S | Chief Scientific Officer | SELL | 10,000 | $14.85 | $148.5K |
| Apr 8, 2026 | LO FRANCIS | Chief People Officer | M | 2,344 | $3.99 | $9.4K |
| Apr 8, 2026 | LO FRANCIS | Chief People Officer | SELL | 22,564 | $15.07 | $340.0K |
| Apr 8, 2026 | LO FRANCIS | Chief People Officer | M | 2,344 | $0.00 | $0.00 |
| Apr 8, 2026 | RUBINSTEIN JULIE | President and COO | M | 14,722 | $7.27 | $107.0K |
| Apr 8, 2026 | RUBINSTEIN JULIE | President and COO | SELL | 30,841 | $14.83 | $457.4K |
10 SEC filing reports analyzed. Sentiment: 1 bullish, 4 bearish, 0 mixed, 5 neutral. Avg impact: 5.2/10.
NEUTRAL
CLUSTER
3/10
Two C-suite insiders at Adaptive Biotechnologies sold a combined $893K in open-market transactions w
Jun 9, 2026
BULLISH
8-K
8/10
Adaptive Biotechnologies reported Q1 2026 revenue of $70.9M (up 35% YoY), beating consensus estimate
May 5, 2026
NEUTRAL
DEFA14A
3/10
Adaptive Biotechnologies (ADPT) is holding its 2026 annual shareholder meeting to vote on three key
Apr 24, 2026
BEARISH
CLUSTER
7/10
Adaptive Biotechnologies (ADPT) saw significant insider selling over a 7-day window, led by CEO Chad
Apr 16, 2026
NEUTRAL
PRESS-RELEASE
3/10
Adaptive Biotechnologies announced an upcoming earnings release for Q1 2026, with no new financial r
Apr 15, 2026
NEUTRAL
CLUSTER
4/10
Four corporate insiders at Adaptive Biotechnologies (ADPT) sold shares in a concentrated 7-day windo
Apr 13, 2026
BEARISH
CLUSTER
8/10
Multiple C-suite executives and directors at Adaptive Biotechnologies sold shares in a concentrated
Mar 14, 2026
BEARISH
CLUSTER
7/10
Adaptive Biotechnologies CEO Chad Robins sold $1.85M in stock, while President Julie Rubinstein exer
Mar 14, 2026
BEARISH
CLUSTER
6/10
Adaptive Biotechnologies COO Julie Rubinstein conducted a series of derivative exercises and open-ma
Mar 11, 2026
NEUTRAL
CLUSTER
3/10
Adaptive Biotechnologies insiders saw a cluster of share award grants across executives and director
Mar 10, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 5 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$20.14 mean target
+16.0% upside
Buy (1.50)
$18.00 Low
$22.00 High
| Metric | Value |
|---|---|
| Current Price | $17.36 |
| Target Low | $18.00 |
| Target Mean | $20.14 |
| Target Median | $20.00 |
| Target High | $22.00 |
| # Analysts | 7 |
| Recommendation | Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.14 | $-0.15 | $-0.11 | 20.3% | +1.0% | 2↑ 3↓ | $0.1B | 11.8% | 7 |
| Next Q 2026-09-30 |
$-0.11 | $-0.12 | $-0.10 | -289.1% | +0.0% | 0↑ 1↓ | $0.1B | -25.2% | 7 |
| Current FY 2026-12-31 |
$-0.46 | $-0.48 | $-0.43 | -17.3% | +2.0% | 0↑ 1↓ | $0.3B | 3.7% | 7 |
| Next FY 2027-12-31 |
$-0.25 | $-0.33 | $-0.17 | 44.7% | +5.3% | 4↑ 3↓ | $0.4B | 22.6% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.135 | |
| 7d ago | $-0.138 | +0.003 |
| 30d ago | $-0.137 | +0.001 |
| 60d ago | $-0.134 | -0.001 |
| 90d ago | $-0.134 | -0.001 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 12, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| May 6, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 6, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 6, 2026 | Guggenheim | REITERATE | Buy | Buy |
| May 6, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 6, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 6, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 26, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
short_volume
Short Volume: ADPT — 58.5% short (0.4M / 0.6M)
Short: 361,774 | Exempt: 1,669 | TRF Vol: 618,652 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
May 29, 2026
other
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers
May 21, 2026
other
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
<p>SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims
May 5, 2026
earnings
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
<p>SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage bi
May 5, 2026
earnings_calendar
ADPT Q1 2026 Earnings After Market Close — 2026-05-05
Apr 15, 2026
earnings
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
<p align="left">SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology co
Apr 9, 2026
short_volume
Short Volume: ADPT — 59.3% short (0.4M / 0.7M)
Short: 397,114 | Exempt: 101 | TRF Vol: 670,000 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: ADPT — 59.1% short (0.4M / 0.6M)
Short: 379,660 | Exempt: 51 | TRF Vol: 642,560 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: ADPT — 64.4% short (0.4M / 0.6M)
Short: 414,163 | Exempt: 0 | TRF Vol: 643,026 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
short_volume
Short Volume: ADPT — 57.6% short (0.5M / 0.8M)
Short: 485,482 | Exempt: 2,585 | TRF Vol: 842,268 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
short_interest
FTD: ADPT — 53,074 shares ($0.7M) failed to deliver
Settlement: 20260401, Price: $13.88, FTD Value: $736,667.12, ADAPTIVE BIOTECHNOLOGIES CORP
Mar 30, 2026
short_interest
FTD: ADPT — 173,482 shares ($2.2M) failed to deliver
Settlement: 20260330, Price: $12.41, FTD Value: $2,152,911.62, ADAPTIVE BIOTECHNOLOGIES CORP
Mar 24, 2026
short_volume
Short Volume: ADPT — 65.2% short (0.4M / 0.6M)
Short: 423,145 | Exempt: 0 | TRF Vol: 648,543 | Short Ratio: 65.2% | Off-exchange volume (dark pool + OTC)
Mar 16, 2026
short_interest
FTD: ADPT — 974,254 shares ($12.8M) failed to deliver
Settlement: 20260316, Price: $13.17, FTD Value: $12,830,925.18, ADAPTIVE BIOTECHNOLOGIES CORP